Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DUMC finds new anti-blood-thinning drug not as safe as protamine
Drug makers have been trying to find an alternative to protamine, which is thought to have a negative effect on blood pressure which has been linked to increased
Drug makers have been trying to find an alternative to protamine, which is thought to have a negative effect on blood pressure which has been linked to increased
Indevus will take over the development and commercialization of Nebido, which recently launched in Europe, in the US. Schering will manufacture and supply commercial product to Indevus. Indevus
The company said its application is expected to receive “priority review” status by the FDA, which means the agency would be required to act on the application within
The firms will evaluate the expression of Scancell’s drug using GTC’s transgenic production platform. GTC says its technology offers significant advantages for the development of proteins that are
The recommendation will form the basis for a European Commission approval, which will enable Noxafil to be marketed in the current 25 EU member states and in Iceland
According to the companies, the trial showed that telbivudine is as effective in chronic hepatitis B patients as the standard treatment lamivudine after one year of use. The
The phase I clinical trial for Cara’s peripherally acting kappa opioid agonist, CR665, demonstrate the treatment to be safe and well-tolerated following intravenous infusion. Furthermore, the resulting plasma
LemnaGene has been researching potential applications of lemna, a small aquatic plant, to produce recombinant proteins. Biolex’s Lex System uses lemna as a transgenic host for the development
The studies follow a previous investigation, results of which suggested CX717 could provide a new approach to enhancing memory cognition and wakefulness by cortical arousal without systemic stimulating
The data come from the largest outcomes study ever conducted in the hemodialysis population. The three-year trial involving more than 2,100 patients compared the difference in mortality and